Evidence map›Paper›PMID 42309468›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2026

Microparticles synthesized from itaconate polyesters enable metabolite delivery and elicit immunoregulatory outcomes.

Amanda N Brocki, Ryan A McIlvaine, Corinne A Martin, Lawrence R Sita, Christopher M Jewell, Senta M Kapnick

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Amanda N BrockiDepartment of Chemistry and Biochemistry, University of Maryland, College Park, MD 20742, USA.
Ryan A McIlvaineFischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA; Robert E. Fischell Institute for Biomedical Devices, University of Maryland, College Park, MD 20742, USA.
Corinne A MartinFischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
Lawrence R SitaDepartment of Chemistry and Biochemistry, University of Maryland, College Park, MD 20742, USA.
Christopher M JewellRobert E. Fischell Institute for Biomedical Devices, University of Maryland, College Park, MD 20742, USA; Veterans Affairs Maryland Health Care System, Department of Veterans Affairs, Baltimore, MD 21201, USA; Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA; Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD 21201, USA.
Senta M KapnickRobert E. Fischell Institute for Biomedical Devices, University of Maryland, College Park, MD 20742, USA; Veterans Affairs Maryland Health Care System, Department of Veterans Affairs, Baltimore, MD 21201, USA. Electronic address: skapnick@umd.edu.

Funding

Zeiss LSM 880 Airyscan Fast Laser Scanning ConfocalS10OD025223 · OD · UNIV OF MARYLAND, COLLEGE PARK · PI BEAVEN, AMY · 2019 to 2019
$557k
BLRD VA IK2 BX005756NIH HHS S10 OD025223
6 · The paper itself

Abstract

Metabolites directly influence immune cell function. Consequently, altering metabolite availability can regulate immunity and represents a window of opportunity for therapeutic manipulation. Itaconate (ITA) - a tricarboxylic acid cycle derivative generated intracellularly - has been shown to exert anti-inflammatory effects in models of autoimmunity. However, efficacy is dependent on systemic, frequent, high-dose treatments due to ITA's poor membrane permeability and rapid clearance from circulation. Thus, there is a need for metabolite delivery strategies that overcome these challenges. Here, we synthesized ITA-based polyesters that enable microparticle (MP) assembly entirely from the polymeric metabolite (pITA). Treatment with biocompatible pITA MPs, which hydrolyze to release unmodified ITA, reduced inflammatory cytokine secretion (e.g., IL-6, IL-1β) by both macrophages and dendritic cells. These data suggest MPs effectively deliver metabolite to the intracellular compartment for immunomodulation in an accessible form. Furthermore, pITA MPs inhibited polarization of inflammatory T cells (T

Indexed as

Anti-Inflammatory AgentsPolyestersSuccinatesAnimalsCytokinesDendritic CellsFemaleMacrophagesMiceMice, Inbred C57BLRAW 264.7 CellsAnti-Inflammatory AgentsCytokinesitaconic acidPolyestersSuccinatesAutoimmunityBiomaterialsImmunometabolismInflammationItaconateMetabolitePolyesters

Identifiers

PMID42309468
PMCPMC13619306

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.